CRISPR/base/prime editing and in-vivo gene therapies plus the broader oncology and rare-disease pipeline in the ADC and GLP-1 era. Pure-play editors (Vertex/CRISPR's Casgevy on-market; Beam and Intellia advancing in-vivo programs) sit alongside big-pharma platforms scaling precision oncology, obesity, and rare-disease franchises.
Browse all macro trends · Product categories · Industries · Companies